Safety of Cream Containing Sericin and Turmeric in Healthy Volunteers
NCT ID: NCT05869357
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
106 participants
INTERVENTIONAL
2023-07-01
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Assessment of Over-the-counter Personal Care and Cosmetic Products Ingredients Based on Product Description
NCT06892067
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT04650256
The Improvement of Black Raspberry in Obese and Mild AZ Patients Infected With H. Pylori
NCT05680532
Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis
NCT06763367
Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin
NCT04045314
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cream containing 2.5% sericin and 2%turmeric
cream containing 2.5% sericin and 2%turmeric
cream containing 2.5% sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream containing 5%sericin and 2%turmeric
cream containing 5% sericin and 2%turmeric
cream containing 5%sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream containing 10%sericin and 2%turmeric
cream containing 10% sericin and 2%turmeric
cream containing 10%sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream base
cream base without sericin and tumeric
cream base
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cream containing 2.5% sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream containing 5%sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream containing 10%sericin and 2%turmeric
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
cream base
Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No skin diseases
* No allergy to sericin and turmeric
* No immunocompromised disease or using steroid for 2 weeks before participated in this study
* Willing to participate in this study
Exclusion Criteria
* Cannot follow the protocol
* Pregnancy and lactation
* Participated in other studies
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pornanong Aramwit, Pharm.D., Ph.D
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pornanong Aramwit, Professor
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EC22010-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.